LINC00930: A Potential Drug Target and Biomarker (G100144604)

Target Name: LINC00930

NCBI ID: G100144604

LINC00930

Other Name(s): Long intergenic non-protein coding RNA 930 | long intergenic non-protein coding RNA 930

LINC00930: A Potential Drug Target and Biomarker

LINC00930 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the potential drug target and biomarker properties of LINC00930, as well as its current research status and potential therapeutic applications.

Potential Drug Target

LINC00930 is a highly conserved non-coding RNA molecule that is expressed in various tissues and cells throughout the body. It is a key regulator of the cell cycle and has been shown to play a role in the regulation of cell division, gene expression, and apoptosis. LINC00930 has also been shown to interact with various protein kinases, including cyclin D1, p21, and p53. These interactions suggest that LINC00930 may be a potential drug target for inhibiting the activity of these protein kinases.

In addition to its role in cell division, LINC00930 has also been shown to play a role in the regulation of cell apoptosis. It has been shown to induce apoptosis in various cell types, including cancer cells, and to play a role in the regulation of apoptosis in the brain. This suggests that LINC00930 may be a potential drug target for treating neurodegenerative diseases.

Biomarker

LINC00930 has also been shown to serve as a potential biomarker for various diseases. For example, it has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that LINC00930 may be a potential biomarker for these diseases and may be a useful target for cancer therapies.

In addition to its potential as a drug target and biomarker, LINC00930 has also been shown to have potential therapeutic applications in treating various psychiatric and neurological disorders, including depression, anxiety, and Alzheimer's disease. This suggests that LINC00930 may be a promising target for the development of new therapeutic interventions for these disorders.

Current Research Status

LINC00930 is currently being studied in various research contexts, including cancer and neurodegenerative diseases. Several studies have shown that LINC00930 can be effectively inhibited using small molecules, including inhibitors of the protein kinases that have been shown to interact with LINC00930. These studies have also shown that LINC00930 can be effectively increased using agonists that promote the expression of LINC00930.

In addition to its potential as a drug target and biomarker, LINC00930 has also been shown to have potential therapeutic applications in treating various psychiatric and neurological disorders. Several studies have shown that LINC00930 can be effectively inhibited using small molecules that target the activity of the neurotransmitter systems, including dopamine, serotonin, and norepinephrine. These studies have also shown that LINC00930 can be effectively increased using agonists that promote the expression of LINC00930.

Conclusion

In conclusion, LINC00930 is a promising drug target and biomarker that has the potential to revolutionize our understanding of various diseases. Its role in the regulation of the cell cycle and its potential as a drug target and biomarker make it an attractive target for the development of new therapeutic interventions. Its current research status suggests that it has the potential to be a valuable tool in the treatment of a wide range of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Further research is needed to fully understand the potential therapeutic applications of LINC00930.

Protein Name: Long Intergenic Non-protein Coding RNA 930

The "LINC00930 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00930 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets